MHRA Approves First UK Treatment for Thyroid Eye Disease
, 2025-05-08 14:20:00 The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza, Amgen) as the first treatment to be licensed in the UK for adults with moderate to severe thyroid eye disease. Thyroid eye disease, also known as Graves’ orbitopathy, affects up to 40% of individuals with this form of hyperthyroidism. Symptoms…